STOCK TITAN

Moderna - MRNA STOCK NEWS

Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.

Moderna (MRNA) remains at the forefront of mRNA technology innovation, developing transformative therapies for infectious diseases, oncology, and rare conditions. This dedicated news hub provides investors and healthcare professionals with essential updates directly from the company and verified sources.

Access official press releases covering clinical trial results, regulatory milestones, and strategic partnerships, alongside analysis of quarterly earnings and pipeline developments. Our curated collection ensures you stay informed about Moderna's progress in advancing mRNA-based medicines without promotional bias.

Key updates include developments in respiratory vaccines, cancer immunotherapy candidates, and rare disease treatments. Bookmark this page for real-time access to Moderna's verified announcements and objective reporting on one of biotechnology's most innovative platforms.

Rhea-AI Summary

Moderna (NASDAQ:MRNA) announces a strategic collaboration with Metagenomi focused on in vivo gene editing therapeutics. The multi-year partnership, covering undisclosed disease targets, includes an upfront cash payment, equity investment, and research funding, with potential milestone and royalty payments. The collaboration aims to leverage Metagenomi's advanced gene editing systems and Moderna's mRNA and LNP technologies to develop transformative therapies for genetic diseases. This partnership strengthens Moderna's portfolio in genomic medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
Rhea-AI Summary

Moderna, Inc. (Nasdaq: MRNA) announced that the FDA requires more time to assess the company's EUA request for the COVID-19 vaccine (mRNA-1273) for adolescents aged 12 to 17. The FDA's review may extend beyond January 2022 due to concerns about myocarditis risk following vaccination. Despite over 1.5 million adolescents vaccinated, Moderna's safety data does not indicate an increased myocarditis risk in this group. Additionally, the filing for pediatric EUA (6-11 years) will be delayed until the FDA completes its review.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
Rhea-AI Summary

Moderna has announced an agreement with Gavi to supply 116.5 million doses of its COVID-19 vaccine in Q2 2022, increasing from a previous 60 million doses. This agreement includes options for an additional 233 million doses under the COVAX Facility, potentially totaling 500 million doses for 2021-2022. All doses will be offered at the lowest tiered price, supporting global access initiatives. The partnership aims to provide vaccines to 92 low- and middle-income countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
covid-19
-
Rhea-AI Summary

Moderna (NASDAQ: MRNA) announces its participation in two upcoming virtual investor conferences:

  • Bernstein Operational Decisions Conference on November 4, 2021 at 4:30 p.m. ET
  • Credit Suisse 30th Annual Healthcare Conference on November 8, 2021 at 1:50 p.m. ET

Live webcasts will be available in the Investors section of Moderna's website and will be archived for at least 30 days post-event. Moderna, a leader in mRNA therapeutics, continues to innovate in vaccine development, notably against COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
none
Rhea-AI Summary

Moderna announced the initiation of the Phase 3 pivotal registration study for mRNA-1647, its cytomegalovirus (CMV) vaccine candidate, marking a significant milestone as it is the second Phase 3 study in the company's history. The CMVictory study aims to enroll around 8,000 participants, primarily women aged 16-40. CMV is the leading infectious cause of birth defects in the U.S., with 1 in 200 babies affected. mRNA-1647 combines six mRNAs targeting CMV proteins and has previously shown promising results in Phase 1 and 2 studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
-
Rhea-AI Summary

Moderna has received authorization from Swissmedic for a 50 µg booster dose of its COVID-19 vaccine, Spikevax, for vulnerable individuals aged 12 and older, at least six months after the primary series. Additionally, a third dose at 100 µg is approved for immunocompromised persons at least 28 days post-second dose. The approvals are backed by clinical data indicating a strong immune response. CEO Stéphane Bancel expressed gratitude for the support, emphasizing the significance of mRNA vaccines against evolving COVID-19 variants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
covid-19
-
Rhea-AI Summary

Moderna has signed a new Memorandum of Understanding (MoU) to provide up to 110 million doses of its COVID-19 vaccine to the African Union. Initial deliveries include 15 million doses in Q4 2021 and 35 million doses in Q1 2022. Moderna will supply these doses at its lowest tiered price as part of its global access commitments. The company is also planning to establish a mRNA vaccine manufacturing facility in Africa by 2023, aiming to produce 500 million doses annually, showcasing its commitment to improve vaccine access in low-income countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
covid-19
Rhea-AI Summary

Moderna (Nasdaq: MRNA) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has approved a booster dose of its COVID-19 vaccine, Spikevax, at a 50 µg level for individuals aged 18 and older, six months post-primary series completion. This recommendation is based on clinical evidence demonstrating a strong immune response, particularly against variants. The safety profile for the booster dose mirrors that of the second dose. Moderna continues to adapt its mRNA technology to respond to evolving COVID-19 challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
covid-19
Moderna

Nasdaq:MRNA

MRNA Rankings

MRNA Stock Data

9.56B
358.52M
7.27%
72.77%
11.68%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE